P. Jewsbury

发表

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.

M. Noble, J. Endicott, N. Curtin, 2003, Bioorganic & medicinal chemistry letters.

Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor

Jane A. Endicott, Thomas G. Davies, Nicola J. Curtin, 2002, Nature Structural Biology.

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.

Stephen Green, J Elizabeth Pease, R. Pauptit, 2003, Bioorganic & medicinal chemistry letters.

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.

Stephen Green, J Elizabeth Pease, Russell T Naven, 2003, Bioorganic & medicinal chemistry letters.

Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.

J. Breed, R. Pauptit, C. Minshull, 2003, Bioorganic & medicinal chemistry letters.

Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.

M. Noble, J. Endicott, J. Bentley, 2006, Journal of medicinal chemistry.

Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.

John G Cumming, J. Breed, P. Jewsbury, 2004, Bioorganic & medicinal chemistry letters.

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

L. Johnson, M. Noble, J. Endicott, 2003, Bioorganic & medicinal chemistry letters.

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.

X. Jacq, J. Nissink, I. Hickson, 2013, Journal of medicinal chemistry.

Abstract 1823: AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity

Lisa L. Smith, P. Caie, X. Jacq, 2012 .

Distal residue-CO interaction in carbonmonoxy myoglobins: a molecular dynamics study of three distal mutants.

P. Jewsbury, T. Kitagawa, Teizo Kitagawa, 1995, Biophysical journal.

Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings

Suzanne F. Jones, Melissa L. Johnson, L. Hart, 2016 .

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice

P. Jewsbury, H. Umehara, R. Wilkinson, 2015, Cancer Immunology, Immunotherapy.

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

S. Barry, S. Ashton, P. Hall, 2016, Science Translational Medicine.

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy

I. Stratford, T. Illidge, P. Jewsbury, 2016, Oncotarget.

A review of protein-small molecule docking methods

Jonathan W. Essex, Richard D. Taylor, Philip J. Jewsbury, 2002, J. Comput. Aided Mol. Des..

8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.

D. Paterson, M. Noble, J. Endicott, 2014, Journal of medicinal chemistry.

N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.

Yuzhu Chen, M. Noble, J. Endicott, 2004, Journal of medicinal chemistry.

Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.

L. Johnson, M. Noble, J. Endicott, 2002, Journal of medicinal chemistry.

Einstein A-coefficients and transition dipole moments for some ion-pair to valence transitions in I2

P. Langridge-Smith, P. Jewsbury, T. Ridley, 1992 .

DETERMINATION OF THE RADIATIVE LIFETIMES OF NINE ION-PAIR STATES OF I2

P. Langridge-Smith, P. Jewsbury, T. Ridley, 1991 .

A model for the relative intensities among ion pair → valence transitions in the heavier halogens and rare gas halides

P. Jewsbury, K. Lawley, 1990 .

REPLACE: A Strategy for Iterative Design of Cyclin‐Binding Groove Inhibitors

P. Fischer, G. Kontopidis, C. McInnes, 2006, Chembiochem : a European journal of chemical biology.

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.

J. Nissink, A. Lau, P. Jewsbury, 2018, Journal of medicinal chemistry.

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

A H Calvert, E. Sausville, L. Johnson, 2000, Journal of medicinal chemistry.

A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models

B. Telfer, I. Stratford, T. Illidge, 2014, International journal of cancer.

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

Philip Smith, J. Riess, B. Cho, 2021, Clinical lung cancer.

THE PROXIMAL RESIDUE LARGELY DETERMINES THE CO DISTORTION IN CARBONMONOXY GLOBIN PROTEINS. AN AB INITIO STUDY OF A HEME PROSTHETIC UNIT

Teizo Kitagawa, Shigeyoshi Yamamoto, Minoru Saito, 1994 .

A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.

Suzanne F. Jones, A. Oza, M. O’Connor, 2016 .

PREDICTION OF TRANSITION STATE STRUCTURE IN PROTEIN TYROSINE PHOSPHATASE CATALYSIS USING A HYBRID QM/MM POTENTIAL

N. Burton, I. H. Hillier, P. Jewsbury, 1997 .

Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.

S. Guichard, P. Jewsbury, R. Odedra, 2013 .

P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy

J. Riess, Paul D. Smith, P. Jewsbury, 2019, Journal of Thoracic Oncology.

The distal residue-CO interaction in carbonmonoxy myoglobins: a molecular dynamics study of two distal histidine tautomers.

P. Jewsbury, T. Kitagawa, Teizo Kitagawa, 1994, Biophysical journal.

Abstract 3343: The pre-clinicalin vitroandin vivoactivity of AZD6738: A potent and selective inhibitor of ATR kinase.

J. Nissink, A. Lau, S. Guichard, 2013 .

FDS: Flexible ligand and receptor docking with a continuum solvent model and soft‐core energy function

Jonathan W. Essex, Richard D. Taylor, Philip J. Jewsbury, 2003, J. Comput. Chem..

A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.

Suzanne F. Jones, J. Barrett, Melissa L. Johnson, 2016 .

Cyclin dependent kinase inhibitors

L. Meijer, M. Noble, J. Endicott, 2003 .

REPLACE: A Strategy for Iterative Design of Cyclin‐Binding Groove Inhibitors

P. Fischer, G. Kontopidis, P. Jewsbury, 2006, Chembiochem : a European journal of chemical biology.

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Mohamed Reda Keddar, P. Jewsbury, D. Morgensztern, 2024, Nature medicine.